rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Immunocore Holdings plc - American Depositary Shares

IMCR · Nasdaq

Health CareBiotechnologyNot moving yet

IMCR stood above a rising 150-day average in 14 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 5.2% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$6.3M
Officials’ trades on record
0
Institutions holding
129 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$23.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months10
Buyers · sellers0 · 4
WhoDidSharesTraded
Bahija JallalCHIEF EXECUTIVE OFFICERsold11,474at $32.3518 Feb 2026filed 19 Feb 2026
John GollSVP, FINANCE & CAOsold698at $32.3518 Feb 2026filed 19 Feb 2026
David M. BermanHEAD OF R&Dsold5,965at $32.3518 Feb 2026filed 19 Feb 2026
Leger Tina Amber StCHIEF HR OFFICERsold1,000at $32.3518 Feb 2026filed 19 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders129-3 on the quarter
New · exited27 · 30
Reported value$1.6B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20265,721,945$181.7M+1,015,777+21.6%
RTW INVESTMENTS, LPunchanged · filed 14 Aug 20264,869,798$154.6M00.0%
FMR LLCreduced · filed 13 Aug 20264,307,246$136.8M-521,908−10.8%
PRIMECAP MANAGEMENT COreduced · filed 14 Aug 20263,638,241$115.5M-55,000−1.5%
Bellevue Group AGreduced · filed 14 Aug 20262,788,245$88.5M-8,558−0.3%
TANG CAPITAL MANAGEMENT LLCunchanged · filed 14 Aug 20262,649,368$84.1M00.0%
Vestal Point Capital, LPreduced · filed 14 Aug 20261,800,000$57.1M-966,868−34.9%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20261,648,983$52.4M+627,718+61.5%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20261,597,037$50.7M+359,634+29.1%
ARMISTICE CAPITAL, LLCadded · filed 14 Aug 20261,428,000$45.3M+240,000+20.2%
31 Mar 2023 – 30 Jun 2026
92114136Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

John Irving Bell Company insiderDirector · last 27 May 20260 · 0
Kristine Peterson Company insiderDirector · last 27 May 20260 · 0
Peter John Ratcliffe Company insiderDirector · last 27 May 20260 · 0
Roy Steven Herbst Company insiderDirector · last 27 May 20260 · 0
Siddharth Kaul Company insiderDirector · last 27 May 20260 · 0
William Pao Company insiderDirector · last 27 May 20260 · 0
Bahija Jallal Company insiderCHIEF EXECUTIVE OFFICER · last 18 Feb 20260 · 1
David M. Berman Company insiderHEAD OF R&D · last 18 Feb 20260 · 15
John Goll Company insiderSVP, FINANCE & CAO · last 18 Feb 20260 · 1
Tina Amber St Leger Company insiderCHIEF HR OFFICER · last 18 Feb 20260 · 3
Travis Alan Coy Company insiderChief Financial Officer · last 17 Feb 20260 · 0
Baker Bros. Advisors (Gp) Llc Company insiderDirector · last 15 May 20250 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202598.7%
Operating profit marginFY 2025 · to 31 Dec 2025-11.3%
Free cash flow marginFY 2025 · to 31 Dec 2025-3.8%
Return on capital employedFY 2025 · to 31 Dec 2025-5.5%
Interest coverFY 2025 · to 31 Dec 2025-3.73×
Research spendFY 2025 · to 31 Dec 202568.7%
Share count trendFY 2025 · to 31 Jan 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$467.7M
Free cash flowFY 2025 · to 31 Dec 2025−$15.1M

Analyst forecasts

No analyst forecasts yet.